{
  "id": "32e5e6a2e4a952f2",
  "title": "STAT+: Nektar Therapeutics is trying to stage a comeback. But a big test awaits",
  "description": "With shares down more than 40% since November, the risk-reward for Nektar Therapeutics has shifted ahead of pivotal clinical trial results.",
  "content": "With shares down more than 40% since November, the risk-reward for Nektar Therapeutics has shifted ahead of pivotal clinical trial results.",
  "source": "STAT",
  "source_url": "https://www.statnews.com/2026/02/05/nektar-therapeutics-eczema-atopic-dermatitis-rezpeg/?utm_campaign=rss",
  "published_at": "2026-02-05T11:30:00+00:00",
  "fetched_at": "2026-02-06T00:27:14.258190+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "ai"
  ],
  "location": null,
  "raw_data": {
    "title": "STAT+: Nektar Therapeutics is trying to stage a comeback. But a big test awaits",
    "description": "With shares down more than 40% since November, the risk-reward for Nektar Therapeutics has shifted ahead of pivotal clinical trial results.",
    "url": "https://www.statnews.com/2026/02/05/nektar-therapeutics-eczema-atopic-dermatitis-rezpeg/?utm_campaign=rss",
    "published": "2026-02-05T11:30:00+00:00",
    "source": "STAT"
  }
}